Commentary: The illusory tinea unguium cure

Daniel, C. Ralph; Jellinek, Nathaniel J.

doi:10.1016/j.jaad.2009.09.001

Cited by 8 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this pilot study, treatment failure occurred in five patients (27.8%) of group I and in 3 (16.7%) of group II, similar to those obtained in other trials (20–30%) 1–3 …”

Section: Discussionsupporting

confidence: 88%

“…In this pilot study, treatment failure occurred in five patients (27.8%) of group I and in 3 (16.7%) of group II, similar to those obtained in other trials (20-30%). [1][2][3] Analysing the aetiological agents and cure rates, we noticed that the two groups showed very similar results. In group I, 12 patients had infection by T. rubrum and nine of them (75%) attained cure (total and partial).…”

Section: Discussionmentioning

confidence: 86%

“…Onychomycosis constitutes up to 50% of all nail disorders 1,2 and its prevalence ranges between 2% and 10% 3,4 . The toenails are generally affected (80% of all cases), mostly due to dermatophytes (specially Trichophyton rubrum ) 3,5–8 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Intermittent therapy with terbinafine and nail abrasion for dermatophyte toe onychomycosis: a pilot study

Succi

Bernardes-Engemann

Orofino-Costa

2013

Mycoses

View full text Add to dashboard Cite

Onychomycosis constitutes up to 50% of all nail disorders. Toenails are generally affected, mostly due to dermatophytes. Terbinafine is the most potent antifungal agent in vitro against dermatophytes. There are few randomised controlled trials using a non-continuous dose of terbinafine. The aim of this open-label pilot study was to reduce the total drug amount, the collateral effects and, specially, the costs; albeit maintaining the same efficacy of the standard regimens. Compare the outcomes of two different intermittent regimens with the same total amount of the medication (42 tablets in 6 months). Forty-one patients were divided into the following groups: terbinafine 250 mg day(-1) , for 7 days, monthly or terbinafine 500 mg day(-1) , once daily, for 7 days, every 2 months, both plus nail abrasion during 6 months. The efficacy was evaluated at months 6, 12 and 18 using the disease free nail criteria. Total cure = group I: eight patients (44.4%) and group II: eight patients (44.4%). Partial cure = group I: five patients (27.8%) and group II: four patients (22.2%). Treatment failure = group I: five patients (27.8%) and group II: three patients (16.7%). Recurrence = group I: zero patients (0.0%) and group II: three patients (16.7%). Two intermittent dosing regimens of terbinafine plus nail abrasion proved to be an alternative statistically effective, safe and with reduced drug costs for dermatophytes toenail onychomycosis.

show abstract

“…In this pilot study, treatment failure occurred in five patients (27.8%) of group I and in 3 (16.7%) of group II, similar to those obtained in other trials (20–30%) 1–3 …”

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 86%

See 1 more Smart Citation

Intermittent therapy with terbinafine and nail abrasion for dermatophyte toe onychomycosis: a pilot study

Succi

Bernardes-Engemann

Orofino-Costa

2013

Mycoses

View full text Add to dashboard Cite

show abstract

“…The disease is often of long duration, is 'more than a cosmetic problem' (Scher,42 1994), significantly affects patients' quality of life (Lubeck et al, 1993) and is recalcitrant to 43 treatment (Arrese and Pierard, 2003;Daniel and Jellinek, 2010). Oral therapy with anti- 44 fungal agents, such as terbinafine and itraconazole, is the treatment mainstay.…”

mentioning

confidence: 99%

UV-curable gels as topical nail medicines:In vivo residence, anti-fungal efficacy and influence of gel components on their properties

Kerai¹,

Hilton²,

Maugueret

et al. 2016

International Journal of Pharmaceutics

View full text Add to dashboard Cite

“…Tinea unguium, tinea das unhas ou onicomicose dermatofítica é uma invasão da lâmina ungueal ocasionada por dermatófitos, considerada uma das micoses de diagnóstico e tratamento mais difíceis 58 . As unhas ficam extremamente frágeis, podendo ocorrer o aparecimento de sulcos, fraturas e calos, com aspecto geralmente amarelado, também podendo ficar arroxeadas ou esbranquiçadas.…”

Section: Formas Clínicasunclassified

Dermatofitoses: agentes etiológicos, formas clínicas, terapêutica e novas perspectivas de tratamento

Lana

Batista

Alves

2016

cbr

View full text Add to dashboard Cite

As dermatofitoses têm ocorrência mundial, sendo mais prevalentes em países de clima tropical e subtropical. Dados epidemiológicos indicam que essas micoses estão entre as infecções fúngicas de maior ocorrência. O quadro clínico mais comum de dermatofitose inclui despigmentação, placas anulares, prurido e perda de cabelo, com lesões tipicamente conhecidas como tineas, ocasionadas por fungos filamentosos dermatofíticos de três gêneros anamórficos: Microsporum, Trichophyton e Epidermophyton. O tratamento das dermatofitoses, em geral, está relacionado ao uso de antifúngicos tópicos e/ou sistêmicos, apresentando como problemática o surgimento de espécies multirresistentes. Esta revisão aborda as dermatofitoses e seus agentes etiológicos de forma aprofundada em aspectos epidemiológicos, apresentando a importância clínica do tema, com ênfase na causa, prevenção, tratamento e prognóstico dessa micose cutânea.

show abstract

Commentary: The illusory tinea unguium cure

Cited by 8 publications

References 29 publications

Intermittent therapy with terbinafine and nail abrasion for dermatophyte toe onychomycosis: a pilot study

Intermittent therapy with terbinafine and nail abrasion for dermatophyte toe onychomycosis: a pilot study

UV-curable gels as topical nail medicines:In vivo residence, anti-fungal efficacy and influence of gel components on their properties

Dermatofitoses: agentes etiológicos, formas clínicas, terapêutica e novas perspectivas de tratamento

Contact Info

Product

Resources

About